Literature DB >> 17275177

Survivin: a promising tumor biomarker.

Michael J Duffy1, Norma O'Donovan, Donal J Brennan, William M Gallagher, Bríd M Ryan.   

Abstract

Survivin is a 16.5 kDa protein overexpressed in almost all malignancies but rarely detected in normal differentiated adult tissues. Functionally, survivin has been shown to inhibit apoptosis, promote cell proliferation and enhance angiogenesis. Consistent with its role in these processes, survivin has been shown to play a key role in cancer progression. Because of the large difference in expression between normal and malignant tissue and its causal role in cancer progression, survivin is currently undergoing intensive investigation as a potential tumor marker. Emerging data suggests that measurement of survivin can aid the early diagnosis of bladder cancer, determine prognosis in multiple cancer types and predict response to diverse anti-cancer therapies. These preliminary findings on the diagnostic, prognostic and predictive potential of survivin should now be confirmed in large prospective trials. Furthermore, assays for the measurement of survivin should be simplified, standardized and evaluated in external quality assurance schemes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17275177     DOI: 10.1016/j.canlet.2006.12.020

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  83 in total

1.  Association between survivin -31G > C promoter polymorphism and cancer risk: a meta-analysis.

Authors:  Xiefeng Wang; Lili Huang; Yanjie Xu; Zhumei Shi; Yingyi Wang; Junxia Zhang; Xirui Wang; Lei Cao; Hui Luo; Jiawei Chen; Ning Liu; Yongmei Yin; Yongping You
Journal:  Eur J Hum Genet       Date:  2012-01-25       Impact factor: 4.246

2.  Relationship of survivin to clinical drug resistance in Burkitt's lymphoma of the head and neck region.

Authors:  Manal M Zyada
Journal:  Med Oncol       Date:  2010-06-04       Impact factor: 3.064

3.  Significance of survivin and Bcl-2 homologous antagonist/killer mRNA in detection of bone metastasis in patients with breast cancer.

Authors:  Samir F Zohny; Mohamed El-Shinawi
Journal:  Med Oncol       Date:  2010-10-27       Impact factor: 3.064

4.  Induction of apoptosis of human colon cancer cells by siRNA recombinant expression vector targeting survivin gene.

Authors:  Ming Cai; Guobin Wang; Kaixiong Tao; Changxue Cai
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-02-18

5.  Survivin and HLA-I expression predicts survival of patients with clear cell renal cell carcinoma.

Authors:  Sulai Liu; Lin Qi; Qiuxia Yu; Yinghui Song; Weiqing Han; Xiongbing Zu; Shusuan Jiang; Jinyang Yuan; Fuhua Zeng; Yu Xie
Journal:  Tumour Biol       Date:  2014-05-23

Review 6.  IAPs: what's in a name?

Authors:  Srinivasa M Srinivasula; Jonathan D Ashwell
Journal:  Mol Cell       Date:  2008-04-25       Impact factor: 17.970

7.  Prognostic value of proliferation markers expression in breast cancer.

Authors:  Natalija Dedić Plavetić; Jasminka Jakić-Razumović; Ana Kulić; Damir Vrbanec
Journal:  Med Oncol       Date:  2013-03-07       Impact factor: 3.064

8.  The role of survivin in diagnosis, prognosis and treatment of breast cancer.

Authors:  Yong-Gang Lv; Fang Yu; Qing Yao; Jiang-Hao Chen; Ling Wang
Journal:  J Thorac Dis       Date:  2010-06       Impact factor: 2.895

9.  Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer.

Authors:  Donal J Brennan; Elton Rexhepaj; Sallyann L O'Brien; Elaine McSherry; Darran P O'Connor; Ailís Fagan; Aedín C Culhane; Desmond G Higgins; Karin Jirstrom; Robert C Millikan; Goran Landberg; Michael J Duffy; Stephen M Hewitt; William M Gallagher
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

10.  Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.

Authors:  Elton Rexhepaj; Karin Jirstrom; Darran P O'Connor; Sallyann L O'Brien; Goran Landberg; Michael J Duffy; Donal J Brennan; William M Gallagher
Journal:  BMC Cancer       Date:  2010-11-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.